Interestingly, NPM1 mutations were already detectable during the MDS phase in 15 cases, namely at very low levels (0.01–1%) in 8 patients and at a median level 10% (range 5–100%), comparable to that observed in sAML phase, in 7 patients. The gene discussed is NPM1; the disease is myelodysplastic syndrome.